Compare FPH & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FPH | XFOR |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | 45 |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 364.6M | 377.3M |
| IPO Year | 2013 | N/A |
| Metric | FPH | XFOR |
|---|---|---|
| Price | $5.18 | $4.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 148.4K | ★ 428.6K |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $110,020,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.40 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.60 | $1.35 |
| 52 Week High | $6.64 | $4.83 |
| Indicator | FPH | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 58.29 | 51.18 |
| Support Level | $4.89 | $3.58 |
| Resistance Level | $5.35 | $4.09 |
| Average True Range (ATR) | 0.15 | 0.22 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 90.91 | 52.29 |
Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational, and recreational elements, as well as civic areas, parks, and open spaces. Its four reportable segments are Valencia, San Francisco, Great Park, and Hearthstone. It derives the majority of revenue from the Great Park segment, which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.